Research Article

DAMPs Synergize with Cytokines or Fibronectin Fragment on Inducing Chondrolysis but Lose Effect When Acting Alone

Table 1

Summary of various types of treatment involving DAPMs examined in the study.

Treatments (DAMPs/Fn-f/proinflammatory cytokines)DosesDownstream effector testedSummary of resultsFigure number

Individual or undefinedSyntheticfMLF1 nM10 nMMMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS(1) Moderate upregulation of pro-MMP-13 only induced in bovine cells
(2) No detectable upregulation of active form of MMP-13 or of other tested effectors
1, 3(a), 3(b), 4, 5(a)
CpG DNA10 μg/mL
rh HMGB110 nMMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS1, 2(a), 2(b), 2(c), 3(a), 3(b), 4, 5(a), 5(b)
rhIL-1β10 ng/mLMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOSStrong upregulation of tested effectors1, 2(a), 3(b), 4(b), 5(b)
rbTNF-α100 ng/mLMMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS2(b), 3(a), 3(b), 4(b), 5(b)

Individual or undefinedNonsyntheticN-terminal 29 kDa Fn-f300 nMMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOSStrong upregulation of tested effectors except iNOS2(a), 3(a), 3(b), 4(a), 5(b)
Injured cartilage-conditioned mediaDay 1 postinjuryMMP-3Strong upregulation of MMP-32(c)

CombinedPairedMTDs10 μg/mL CpG DNA + 1 nM fMLF10 μg/mL CpG DNA + 10 nM fMLFMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOSNo detectable upregulation of tested effectors1, 2(a), 2(b), 2(c), 3(a), 3(b), 4, 5(a), 5(b)
Fn-f with individual DAMPs or proinflammatory cytokines300 nM Fn-f + 10 nM HMGB1MMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS(1) Strong upregulation of tested effectors
(2) Marked synergism between Fn-f and cytokines observed in MMP-3 upregulation
(3) In human cells, moderate synergism observed between HMGB1 and Fn-f on upregulating MMP-3, MMP-13, and ADAMTS-5
2(a), 3(a), 4, 5(b)
300 nM Fn-f + 10 ng/mL IL-1β
300 nM Fn-f + 100 ng/mL TNF-α
Proinflammatory cytokines or with individual DAMPs10 ng/mL IL-1β + 100 ng/mL TNF-αMMP-3(1) IL-1β and TNF-α induced the most MMP-3 protein expression
(2) Moderate synergism shown between TNF-a and HMGB1
2(b)
100 ng/mL TNF-α + 10 nM HMGB1
10 ng/mL IL-1β + 10 nM HMGB1MMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOSStrong synergism shown between HMGB1 and IL-1β on upregulating MMP-3, MMP-13, ADAMTS-5, ADAM-8, or iNOS2(a), 2(b), 3(b), 4(b), 5(b)
CombinedTripleMTDs with Fn-f or proinflammatory cytokines10 μg/mL CpG DNA + 10 nM fMLF + 10 nM HMGB1MMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS(1) In bovine cells, moderate upregulation of pro-MMP-13 induced weaker effect in human cells
(2) No detectable upregulation of active MMP-13 or other tested effectors
2(a), 2(b), 3(a), 3(b), 4, 5(b)
10 μg/mL CpG DNA + 10 nM fMLF + 300 nM fMLFMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS(1) Strong upregulation of tested effectors expect iNOS
(2) Synergism not observed
2(a), 3(a),
4(a), 5(b)
10 μg/mL CpG DNA + 10 nM fMLF + 10 ng/mL IL-1βMMP-1, MMP-13, ADAMTS-5,
ADAM-8, iNOS
(1) Strong upregulation of tested effectors
(2) Moderate synergism observed on upregulating MMP-13 or iNOS
2(b), 3(a), 4(b), 5(b)
10 μg/mL CpG DNA + 10 nM fMLF + 100 ng/mL TNF-αMMP-3HMGB1 and IL-1β showed much stronger synergism with TNF-α than MTDs did2(b)
Proinflammatory cytokines with HMGB1 or Fn-f10 nM HMGB1 + 10 ng/mL
IL-β + 100 ng/mL TNF-α
300 nM Fn-f + 10 ng/mL
IL-β + 100 ng/mL TNF-α
MMP-1, MMP-3, MMP-13, ADAMTS-5Strong upregulation of tested effectors2(a)

CombinedQuaternaryDAMPs with Fn-f or proinflammatory cytokines10 μg/mL CpG DNA + 10 nM fMLF + 10 nM HMGB1 + 300 nM Fn-fMMP-1, MMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOSStrong upregulation of tested effectors except iNOS2(a), 3(a), 4(a), 5(b)
10 μg/mL CpG DNA + 10 nM fMLF + 10 nM HMGB1 + 10 ng/mL IL-1βMMP-3, MMP-13, ADAMTS-5, ADAM-8, iNOS(1) Strong upregulation of tested effectors
(2) Marked synergism observed on upregulating MMP-3, MMP-13, or iNOS
3(b), 4(b), 5(b)
10 μg/mL CpG DNA + 10 nM fMLF + 10 ng/mL
IL-1β + 100 ng/mL TNF-α
MMP-3Strong upregulation of MMP-3 observed but no synergism between MTDs and cytokines detected2(b)